Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06667908 · ClinicalTrials.gov registry record · Phase 2

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Johnson & Johnson Enterprise Innovation.

Recruiting
Registry status
Phase 2
Development phase
130
Enrollment target
20
Study locations

NCT06667908: Recruiting Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Johnson & Johnson Enterprise Innovation.

NCT06667908 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Johnson & Johnson Enterprise Innovation. The registered enrollment target is 130 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06667908, a Phase 2 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Johnson & Johnson Enterprise Innovation.

RECRUITING
Registry status
Phase 2
Development phase
130 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.

Primary Outcome

ORR is defined as the percentage of participants who have a best response of complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1 using ICR assessments.

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • BIOLOGICAL Durvalumab
  • DRUG JNJ-90301900
  • RADIATION Concurrent Chemo/Radiation Therapy (cCRT)
  • DRUG Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin
  • DRUG Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel

Study Locations (20)

Other

  • Royal Brisbane and Women's Hospital - Herston
  • Sir Charles Gairdner Hospital - Nedlands
  • Macquarie University - North Ryde
  • Royal Melbourne Hospital - Parkville
  • Fundacao Pio XII - Barretos
  • Sociedade Beneficente de Senhoras Hospital Sirio Libanes - São Paulo
  • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein - São Paulo

Connecticut

  • University of Connecticut Health Center - Farmington
  • Yale University - New Haven

Florida

  • University of Miami - Miami
  • Orlando Health Cancer Institute - Orlando

New York

  • NYU Langone Health - New York
  • Memorial Sloan Kettering Cancer Center - New York

North Carolina

  • University of North Carolina at Chapel Hill - Chapel Hill
  • FirstHealth of the Carolinas - Pinehurst

Georgia

  • Emory University Winship Cancer Institute - Atlanta

Oregon

  • Oregon Health And Science University - Portland

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2024-12-06
Est. Completion 2028-12-31
Phase Phase 2
Johnson & Johnson Enterprise Innovation

7 total trials

What NCT06667908 shows while recruiting

NCT06667908 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (60% lower).

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which Durvalumab is the first listed.

NCT06667908 names 20 study sites across 10 states, led by Other, Connecticut, Florida.

Frequently Asked Questions

What is clinical trial NCT06667908 about?

NCT06667908 is a clinical study titled "A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is compl...

What is the current status of trial NCT06667908?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2024-12-06. Estimated completion is 2028-12-31.

What conditions does trial NCT06667908 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT06667908?

The interventions under investigation include: Durvalumab (BIOLOGICAL), JNJ-90301900 (DRUG), Concurrent Chemo/Radiation Therapy (cCRT) (RADIATION), Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin (DRUG), Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel (DRUG).

Who is sponsoring clinical trial NCT06667908?

This trial is sponsored by Johnson & Johnson Enterprise Innovation, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06667908 being conducted?

This trial has 20 study locations across Connecticut, Florida, Georgia, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06667908's enrollment target sits among peer trials

130 62nd of 130 higher than 68 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01492036 · 130 participants

    Long-Term Follow-Up of Recipient of Gene Transfer Research

  • NCT01631617 · 130 participants · Phase 2

    Effects of Treatments on Atopic Dermatitis

  • NCT02368041 · 130 participants

    Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure

  • NCT02604277 · 130 participants · NA

    Suicidal Behavior in Patients Diagnosed With Bipolar Disorder

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06667908

Source: ClinicalTrials.gov NCT06667908, the US trial registry maintained by the National Library of Medicine. NCT06667908 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.